Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 12/20 | 0.36 |
| ▸ | HSP90B1 | P14625 | 7/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17623871 | 0.84 | HSP90AA1 (0.45) | HSP90AA1HSP90B1TIPARP | |
| SCHEMBL12769069 | 0.82 | HSP90AA1 (0.39) | HSP90AA1HSP90B1SLC29A1 | |
| SCHEMBL17623869 | 0.82 | HSP90AA1 (0.43) | HSP90AA1HSP90B1 | |
| SCHEMBL12840038 | 0.78 | HSP90AA1 (0.40) | HSP90AA1HSP90B1CYP2C19 | |
| SCHEMBL12840947 | 0.77 | HSP90AA1 (0.39) | HSP90AA1HSP90B1 | |
| SCHEMBL17623867 | 0.74 | HSP90AA1 (0.45) | HSP90AA1HSP90B1 | |
| SCHEMBL12769043 | 0.73 | HTR2C (0.34) | SLC29A1 | |
| SCHEMBL12840031 | 0.71 | CHRM2 (0.37) | CHRM1CYP2C19 | |
| SCHEMBL8222559 | 0.71 | HSP90AA1 (0.50) | HSP90AA1HSP90B1CYP2C19 | |
| SCHEMBL19504483 | 0.71 | CCNA2 (0.46) | HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910596-B2 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20100234403-A1 | Aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK & CO., INC. | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234403-A1 | Aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | HSP90AA1 3908/4885HSP90B1 3188/4885SLC29A1 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.